Company Description
RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases.
Its lead inflammation drug candidate is RPT193, a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.
The company's lead oncology drug candidate is FLX475, an oral small molecule CCR4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer.
It also focuses on the development of hematopoietic progenitor kinase 1 inhibitor.
The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019.
RAPT Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
| Country | United States |
| IPO Date | Oct 31, 2019 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 70 |
| CEO | Dr. Brian Russell Wong M.D., Ph.D. |
Contact Details
Address: 561 Eccles Avenue South San Francisco, California United States | |
| Website | https://www.rapt.com |
Stock Details
| Ticker Symbol | RAPT |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001673772 |
| CUSIP Number | 75382E109 |
| ISIN Number | US75382E1091 |
| Employer ID | 47-3313701 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Brian Russell Wong M.D., Ph.D. | Chief Executive Officer, President & Director |
| Rodney K. B. Young | Chief Financial Officer, Principal Accounting Officer & Secretary |
| Dr. David Wustrow | Senior Vice President of Drug Discovery & Preclinical Development |
| Dr. Dirk G. Brockstedt Ph.D. | Chief Scientific Officer |
| Dr. Paul Kassner | Senior Vice President of Quantitative & Computational Biology |
| Dr. William Ho M.D., Ph.D. | Chief Medical Officer |
| Gwen R. Carscadden | Chief Human Resources Officer |
| Jennifer Nicholson | Senior Vice President of Regulatory Affairs & Quality Assurance |
| Michael Listgarten | General Counsel |
| Steve Young Ph.D. | Vice President of Technology |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 15, 2024 | 4 | Filing |
| Nov 15, 2024 | 4 | Filing |
| Nov 15, 2024 | 4 | Filing |
| Nov 15, 2024 | 4 | Filing |
| Nov 15, 2024 | 8-K | Current Report |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 12, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 12, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 12, 2024 | 8-K | Current Report |